BridgeMD
New treatment option for Enlarged Prostate With Lower Urinary Tract Symptoms
Official title Medications for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
ClinicalTrials.gov ID: NCT06491108
What this study is testing
What is Vardenafil 5 Mg Oral Tablet?
Vardenafil 5 Mg Oral Tablet is an investigational medicine, given as an once-daily pill taken by mouth, being studied as a potential treatment for enlarged prostate with lower urinary tract symptoms.
Also referred to as Vardenafil 5 mg.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The main objective of this prospective randomized controlled study is to compare safety and efficacy of Vardenafil versus Tadalafil versus Tamsulosin in terms of (voiding function, sexual function and quality of life) in the management of moderate BPH related LUTS.
- Phase 3: a large, late-stage study
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 40 to 70, men only
You may be able to join if
- Sexually active patients .
- ModerateBPH related LUTS ( bengin prostatic hyperplasia related lower urinary tract symtoms ) i.e: (international prostatic symptom score 8 to 19...
- Patients accepted medical treatment and completed 12 weeks on medical treatment and strict follow up .
You likely can't join if
- Indication for combined therapy as prostate size over 40 gm .
- Gross hematuria.
- Refractory urine retention .
- Bilateral hydro-ureteronephrosis or renal insufficiency secondary to bengin prostatic hyperplasia.
- Bladder diverticula or calculi .
- History of bladder or prostate cancer.
See the full eligibility criteria
- Sexually active patients .
- ModerateBPH related LUTS ( bengin prostatic hyperplasia related lower urinary tract symtoms ) i.e: (international prostatic symptom score 8 to 19 : the higher score is the worse symptoms ).
- Patients accepted medical treatment and completed 12 weeks on medical treatment and strict follow up .
- Indication for combined therapy as prostate size over 40 gm .
- Gross hematuria.
- Refractory urine retention .
- Bilateral hydro-ureteronephrosis or renal insufficiency secondary to bengin prostatic hyperplasia.
- Bladder diverticula or calculi .
- History of bladder or prostate cancer.
- Unwilling patients to medical therapy.
- History of pelvic surgery or urethral stricture.
The study team makes the final eligibility decision.
Where it's taking place
- Tanta, Gharbia Governorate, Egypt
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling male, 40 years to 70 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Tanta, Gharbia Governorate, Egypt. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.